We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug & Device Products
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Publications
    • Webinar Training Pass
    • eCFR and Guidances
    • Books
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Sanofi, AstraZeneca Collaborate to Share 210,000 Compounds

Sanofi, AstraZeneca Collaborate to Share 210,000 Compounds

November 30, 2015

Sanofi and AstraZeneca are touting an innovative, open model of collaboration that will see the direct exchange of 210,000 compounds between the two companies’ proprietary libraries.

Announced in late November, the deal gives both companies free access to each other’s usually closely guarded compounds. Each company is free to develop any of the shared compounds without any financial obligation and without restrictions on targeted disease areas.

The collaboration will enhance the chemical diversity of the compound collections and allow them to screen a broader, more diverse chemical group as the starting point in developing new small-molecule drugs.

The exchanged compounds specifically were selected to play off differences from their own current libraries, the companies say. They will be exchanged in large enough quantities to enable the receiving company to carry out high throughput screening for several years to determine if they are active against a certain target. If a compound matches a target, it then can be modified to optimize its structure before being classified as a “lead compound” and entering development.

Even though the drugmakers work in similar disease areas like oncology, there is little chance that they would develop similar drugs even using the same compound, because the companies have different R&D methods.

This is a unique agreement, as large pharmaceutical companies typically seek to expand their pipelines by licensing drugs from smaller biotech firms, or just buying them outright. AstraZeneca also has struck compound sharing agreements with smaller companies, but nothing at this scale with a major player like Sanofi.

Pharmaceuticals Research and Development Commercial Operations

Upcoming Events

  • 08Sep

    Organizing Data and Document Archives: Finding a Needle in a Haystack for FDA Inspections

  • 15Sep

    Califf’s Post-PDUFA, Post-COVID FDA Agenda: Key Developments, Insights and Analysis

  • 20Sep

    Building a World-Class Pharmaceutical Advertising and Promotion Review Program

  • 21Sep

    The FDA’s Focus on Clinical Data Integrity Throughout Product Development and Approval

  • 22Sep

    FDA’s New Quality Management System Regulation: What the Proposed Harmonization with ISO 13485 Means for Devicemakers

  • 11Oct

    1st Annual Quality Management vSummit

Featured Products

  • FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

    FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

  • Selecting and Implementing Electronic Document Management Systems in the EU

    Selecting and Implementing Electronic Document Management Systems in the EU

Featured Stories

  • Thermo Fisher Scientific Gets FDA Premarket Approval for Companion Diagnostic

  • MHRA Grants Conditional Authorization to Moderna’s Bivalent COVID-19 Booster Vaccine

  • Organogenesis Gets 510(k) Clearance to Expand PuraPly Portfolio

  • FDA Grants Priority Review to sNDA for Lynparza

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing